CRISPR Therapeutics AG (NASDAQ:CRSP) is one of the 10 Stocks Going Wild. Crispr Therapeutics rallied for a second day on ...

CRISPR Therapeutics (CRSP) saw its shares surge in the last session with trading volume being higher than average. The latest ...

Analysts have also weighed in on stock throughout the month. Recent analyst calls on the stock include: Needham analyst Gil ...

The largest transaction of the day was ARK’s acquisition of 102,806 shares of CRISPR Therapeutics AG (NASDAQ: CRSP ), valued at approximately $5.26 million. This purchase through the ARKK ETF reflects ...

Cathie Wood's ARKK hits a 52-week high after bold biotech moves, signaling renewed momentum in disruptive tech.

A high-level overview of CRISPR Therapeutics AG (CRSP) stock. View (CRSP) real-time stock price, chart, news, analysis, analyst reviews and more.

Regenerative medicine is gaining serious momentum in 2025 as scientific advances, regulatory progress, and payer acceptance converge to push the sect ...

The First Trust Rising Dividend Achievers ETF (RDVY) made its debut on 01/07/2014, and is a smart beta exchange traded fund ...

Each year, approximately 20 million people are diagnosed with cancer, and nearly 10 million lives are lost to the disease ...

We came across a bullish thesis on Verve Therapeutics, Inc. on Stock Region Research’s Substack by Stock Region. In this ...

Review the current CRISPR Therapeutics AG (CRSP:XNAS) dividend yield and history to decide if CRSP is the best investment for you.